|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 April 2006, Vol. 107, No. 8, pp. 3408-3409.
CORRESPONDENCE To the editor:Increased soluble urokinase plasminogen activator receptor (suPAR) serum levels after granulocyte colony-stimulating factor treatment do not predict successful progenitor cell mobilization in vivoHematopoietic stem cell (HSC) mobilization is still not well understood. Accumulating evidence suggests that protease activation is an important step: proteases release cytokines or chemokines from the extracellular matrix, thereby modulating biological responses.1,2 The urokinase-type plasminogen activator receptor (uPAR) is the receptor for urokinase-type plasminogen activator (uPA). The ligand uPA cleaves uPAR between domains I and II, liberating domain I—uPAR(I)—while uPAR(II-III) remains on the cell surface.3 Proteases cleave uPAR(I-III) and soluble urokinase plasminogen activator receptor (suPAR) (I-III) in vitro,3-5 unmasking a region with chemotactic properties.6 Recently, a role of suPAR for granulocyte colony-stimulating factor (G-CSF)–mediated HSC mobilization in allogeneic donors has been proposed in this journal.7 Results we obtained in autologous patients receiving chemotherapy prior to G-CSF, however, challenge the proposed role for suPAR in certain settings of G-CSF–mediated HSC mobilization. Serum samples were collected at our center before G-CSF and/or prior to leukapheresis from healthy allogeneic donors and autologous patients, most of whom were suffering from lymphoid malignancies in remission of the disease. The G-CSF dose for donors was 2 x 5 or 2 x 8 µg/kg body weight per day (BW/d) subcutaneously. Leukapheresis was performed on day 5 of G-CSF. Autologous patients were mobilized with chemotherapy chosen for optimal stem cell mobilization and disease control. G-CSF (5 or 10 µg/kg BW/d subcutaneously) was started 6 days before scheduled leukapheresis. Blinded serum samples were analyzed with time-resolved fluoroimmunoassays by measuring uPAR variants concentrations before and after uPAR depletion.8 Accuracy was determined by measuring recoveries of spiked standards in 20% (vol/vol) serum pool in buffer. Progenitor cell mobilization was similar in autologous patients (mean CD34+ cell count on the day of leukapheresis, 84 128 ± 15 893/mL [SEM] blood; n = 66) and allogeneic donors (79 470 ± 10 710/mL; n = 21). However, leukocyte counts on the day of leukapheresis were inferior for autologous pts (20.89 ± 1.46/nL, n = 66, compared with 49.6 ± 2.5/nL in allogeneic donors; n = 28, P < .001, unpaired t test).
Before G-CSF administration, suPAR(I-III), suPAR(I), or suPAR(II-III) levels were identical in both groups (Figure 1A-C). Serum levels for full-length suPAR(I-III) significantly increased in the pooled allogeneic and autologous group after G-CSF administration (Figure 1A), but mean suPAR(I-III) levels were lower in autologous patients than in allogeneic donors. An increase in suPAR(II-III) and suPAR(I) levels was found in serum from allogeneic but not from autologous patients after G-CSF (Figure 1B-C). In paired samples, G-CSF significantly augmented serum levels of the different suPAR forms in allogeneic donors, confirming recently published results (Figure 1D-F).7 In contrast, however, in serum from the autologous group, neither full-length suPAR(I-III) and suPAR(II-III) levels, nor suPAR(I) levels, increased after chemotherapy plus G-CSF treatment (Figure 1G-I). Most importantly, serum levels for full-length (Figure 1J-K) or cleaved suPAR (data not shown) after G-CSF administration did not correlate with CD34+ counts in both groups, but did correlate with leukocyte counts (data not shown). On the basis of our data, we propose that the leukocyte increase after G-CSF is responsible for higher full-length suPAR serum levels, possibly through G-CSF–mediated induction of proteases in neutrophils.8 A successful progenitor cell mobilization after G-CSF treatment, as observed in the patient group receiving chemotherapy, does not necessarily correlate with increased suPAR serum levels.
Correspondence: Beate Heissig, Stem Cell Regulation, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, 108-8639 Tokyo, Japan; e-mail: b_heissig{at}yahoo.com.
Supported by grants from the Leukemia & Lymphoma Foundation (B.H.) and Grants-in-Aid from the Ministry of Education, Science, Technology, Sports, and Culture, Japan (K.H.). We thank Jesper Pass and Gunilla Høyer-Hansen (grant support, European Union Framework Program 6 project LSHC-CT-2003-503297) for their continuous support, for providing vital analytical tools, and for performing the suPAR analysis, as well as the Finsen laboratory, Copenhagen, Denmark (laboratory head, Keld Dano).
T.F. designed and performed research, analyzed data, and wrote the letter; K.H. designed research; E.T. designed research and reviewed the letter; and B.H. designed research, analyzed data, and wrote the letter.
References
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
